Brokerages Set GSK PLC Sponsored ADR (NYSE:GSK) Price Target at $53.00

GSK PLC Sponsored ADR (NYSE:GSK) has received a consensus rating of “Reduce” from the ten analysts that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $53.00.

Several research firms have recently commented on GSK. Barclays reiterated an “underweight” rating on shares of GSK in a research note on Friday, February 20th. Wall Street Zen cut shares of GSK from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 7th. Weiss Ratings raised shares of GSK from a “hold (c+)” rating to a “buy (b)” rating in a report on Friday. Citigroup reaffirmed a “neutral” rating on shares of GSK in a report on Monday, February 9th. Finally, TD Cowen reaffirmed a “hold” rating on shares of GSK in a report on Monday, February 9th.

GSK Price Performance

NYSE GSK opened at $51.65 on Monday. The firm’s fifty day simple moving average is $55.78 and its two-hundred day simple moving average is $51.73. The company has a current ratio of 0.79, a quick ratio of 0.52 and a debt-to-equity ratio of 0.80. GSK has a 12-month low of $35.45 and a 12-month high of $61.69. The firm has a market capitalization of $104.80 billion, a P/E ratio of 13.42, a P/E/G ratio of 2.63 and a beta of 0.38.

GSK (NYSE:GSK) last released its quarterly earnings results on Thursday, February 5th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.04. GSK had a net margin of 17.82% and a return on equity of 44.28%. The business had revenue of $11.59 billion for the quarter, compared to analyst estimates of $8.48 billion. During the same period in the previous year, the company earned $0.23 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. Analysts forecast that GSK will post 4.88 EPS for the current fiscal year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 9th. Shareholders of record on Friday, May 15th will be issued a $0.44 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $1.76 dividend on an annualized basis and a yield of 3.4%. GSK’s payout ratio is presently 48.83%.

Key GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK announced a quarterly dividend of $0.44 per share (annualized yield ~3.4%), with shareholders of record May 15 and payment scheduled July 9 — a cash-return signal that tends to support the share price and income-oriented investors.
• Positive Sentiment: GSK Canada secured priority review for bepirovirsen, a potential functional cure therapy for chronic hepatitis B — regulatory progress on a high-value asset could be a meaningful mid/long-term value driver if approved. GSK Canada priority review
• Positive Sentiment: Q1 2026 results showed solid sales growth (~5%) led by specialty medicines and vaccines and management highlighted strategic pipeline expansion — the quarter reinforced underlying cash flow and earnings stability. Q1 2026 earnings call highlights
• Neutral Sentiment: Analyst commentary and value screens highlight GSK as a long-term value pick for some investors (Zacks coverage), which can attract longer-horizon buyers but may have limited near-term price impact. Zacks analysis
• Negative Sentiment: GSK-partnered Alzheimer’s asset from Alector failed its Phase 2 study — another neuro program disappointment that raises questions about late-stage neuroscience returns and could reduce pipeline valuation. Alector Alzheimer’s failure
• Negative Sentiment: J.P. Morgan reiterated an underweight rating with a £17 price target, citing limited near-term earnings upgrade potential and dependence on successful launches and pipeline readouts — this downgrades street sentiment and can pressure the stock. JP Morgan underweight

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Horizon Corp increased its stake in shares of GSK by 78.7% during the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 236 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in shares of GSK during the fourth quarter worth about $30,000. CNB Bank purchased a new stake in shares of GSK during the third quarter worth about $31,000. Triumph Capital Management purchased a new stake in shares of GSK during the third quarter worth about $40,000. Finally, Salomon & Ludwin LLC increased its stake in shares of GSK by 444.0% during the third quarter. Salomon & Ludwin LLC now owns 952 shares of the pharmaceutical company’s stock worth $41,000 after purchasing an additional 777 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.